Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Verapamil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Societal CDMO
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.
Product Name : Verelan PM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 07, 2022
Lead Product(s) : Verapamil Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Societal CDMO
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cocaine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Receives Fda Approval To Manufacture Numbrino® At Seymour Plant
Details : Numbrinoâ„¢ (Cocaine Hydrochloride Nasal Solution) company's branded topical anesthetic product for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.
Product Name : Numbrino
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : Cocaine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : HEC Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Announces Subject Dosing Complete For Pivotal Clinical Trial Of Biosimilar Insulin Glargine
Details : Biosimilar insulin glargine is the most significant opportunity in the company's current pipeline. Recent estimated U.S. sales of long acting insulin glargine (Glaricon) are approximately $10 billion annually, according to IQVIA, although manufacturer re...
Product Name : Glaricon
Product Type : Peptide
Upfront Cash : Inapplicable
August 31, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : HEC Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Initiates Pivotal Clinical Trial for Biosimilar Insulin Glargine
Details : The first study, which the FDA reviewed, suggested that the HEC insulin glargine product would be biosimilar to US-approved Lantus® (the reference biologic) in terms of meeting the study's pharmacokinetics (PK) and pharmacodynamics (PD) endpoints.
Product Name : Glaricon
Product Type : Peptide
Upfront Cash : Inapplicable
March 29, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Parexel | Farmovs
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
February 21, 2022
Lead Product(s) : Insulin Glargine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Parexel | Farmovs
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Recipient : HEC Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
Details : The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
September 02, 2021
Lead Product(s) : Insulin aspart
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Recipient : HEC Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Recipient : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
LANNETT Expands Respiratory Pipeline, Signs Exclusive Commercialization
Details : Lannett Company has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva® Handihaler® (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 29, 2021
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Submits ANDA For Generic ADVAIR DISKUS®
Details : Respirent Pharmaceuticals has summited an Abbreviated New Drug Application for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the U.S. FDA. The product is the generic equivalent of ADVAIR DISKUS of Glax...
Product Name : Flovent Diskus
Product Type : Steroid
Upfront Cash : Inapplicable
January 04, 2021
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Lannett announced that it has entered into an exclusive U.S. distribution agreement for the therapeutically equivalent generic of Flovent® Diskus® (Fluticasone Propionate Powder Inhaler) of Respirent Pharmaceuticals.
Product Name : Flovent Diskus
Product Type : Steroid
Upfront Cash : Undisclosed
August 17, 2020
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Respirent Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Mexiletine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : RIVOPHARM SA
Deal Size : Undisclosed
Deal Type : Collaboration
Lannett Launches Mexiletine HCl Capsules
Details : Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 23, 2020
Lead Product(s) : Mexiletine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : RIVOPHARM SA
Deal Size : Undisclosed
Deal Type : Collaboration